Cancer Research and Treatment

Original Articles

Breast cancer

Short-term Impact of Hormone Replacement Therapy on Risk of Breast Cancer in BRCA Mutation Carriers: A Nationwide Study in South Korea: Hye Yeon Kim, Jisoo Park, Seok Joo Moon, Sohyeon Jeong, Jin Hwa Hong, Jae Kwan Lee, Geum Joon Cho, Hyun-Woong Cho; Cancer Res Treat. 2024;56(1):143-148. Published online August 16, 2023; DOI: https://doi.org/10.4143/crt.2023.653

Purpose
BRCA1/2 mutations are well-known risk factors for breast and ovarian cancers in women. Risk-reducing salpingo-oophorectomy (RRSO) is the standard treatment for preventing ovarian cancer with BRCA mutations. Postmenopausal syndrome (symptoms after RRSO can be alleviated by hormone replacement therapy (HRT); however, the use of HRT in carriers of BRCA mutations has been controversial because of the concern that HRT increases the risk of breast cancer. This study aimed to evaluate the effects of HRT in BRCA mutation carriers who underwent RRSO.
Materials and Methods
A total of 151 carriers, who underwent RRSO between 2013 and 2020 after the diagnosis of BRCA1 or BRCA2 mutations were selected and followed up for a median of 3.03 years. Patients were divided into two groups: those who received HRT after RRSO (n=33) and those who did not (n=118). We compared the incidence of breast cancer over time between these two groups.
Results
There was no significant difference in the incidence of breast cancer between women who received HRT and those who did not (p=0.229). Multivariate logistic regression analysis, adjusted for age and parity revealed no significant difference in the risk of breast cancer between these two groups (hazard ratio, 0.312; 95% confidence interval, 0.039 to 2.480; p=0.278).
Conclusion
In this study, we found no relationship between post-RRSO HRT and breast cancer in the population with BRCA mutations. Therefore, healthcare providers may consider the alleviation of symptoms of postmenopausal syndrome through HRT in patients who underwent RRSO.

Citations

Citations to this article as recorded by

A contemporary review of breast cancer risk factors and the role of artificial intelligence
Orietta Nicolis, Denisse De Los Angeles, Carla Taramasco
Frontiers in Oncology.2024;[Epub] CrossRef

3,095 View
247 Download
1 Web of Science
1 Crossref

Genitourinary cancer

A Nationwide Study of Differences in Surgical Treatment Rates and Oncological Outcomes for Prostate Cancer according to Economic Status and Region: Sangjun Yoo, Sohee Oh, Min Chul Cho, Hwancheol Son, Hyeon Jeong; Cancer Res Treat. 2023;55(2):652-658. Published online December 12, 2022; DOI: https://doi.org/10.4143/crt.2022.893

Abstract PDF Supplementary Material PubReader ePub: Purpose
We investigated the effects of economic status (classified based on insurance type and residential area) on oncological outcomes of prostate cancer using a nationwide database. We additionally investigated oncological outcomes based on economic status and residential area in patients who underwent surgical treatment.
Materials and Methods
The study included 75,518 men with newly diagnosed prostate cancer between 2009 and 2018 in whom oncological outcomes were investigated based on economic status and residential area. Among the 75,518 men with prostate cancer, the data of 29,973 men who underwent radical prostatectomy were further analyzed. Multivariate analysis was performed to determine the effects of economic status and residential area on postoperative oncological outcomes.
Results
Among the 75,518 patients with prostate cancer, 3,254 (4.31%) were medical aid beneficiaries. The 5-year overall survival rates were 81.2% and 64.8% in the health insurance and medical aid groups, respectively. Radical prostatectomy was more common in the health insurance group, and surgical intervention was significantly affected by the residential area. Among patients who underwent surgery, 5-year androgen deprivation therapy–free and overall survival were better in the health insurance group. Multivariate analysis showed that insurance type and residential area were significantly associated with the androgen deprivation therapy–free and overall survival after adjustment for other variables.
Conclusion
Economic status and residential area were shown to affect not only treatment patterns but also post-diagnosis and postoperative oncological outcomes. Political support for early diagnosis and appropriate treatment of prostate cancer is warranted for medically vulnerable populations.

4,067 View
124 Download

Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment: Won-Il Choi, Jiah Choi, Mi-Ae Kim, Gyumin Lee, Jihyeon Jeong, Choong Won Lee; Cancer Res Treat. 2019;51(3):1241-1248. Published online December 31, 2018; DOI: https://doi.org/10.4143/crt.2018.513

Abstract PDF PubReader ePub

Purpose
We aimed to determine the demographic and epidemiologic variables that are associated with no treatment in lung cancer patients.
Materials and Methods
Patient data were collected from the Korean National Health Insurance Database. The lung cancer group included patients with an initial diagnosis of lung cancer between January 2009 and December 2014. Treated cases were defined as those that underwent surgery, radiation, or chemotherapy until death, after the diagnosis of lung cancer. Risk of no treatment was calculated by multiple logistic regression analysis.
Results
Among the 2148 new cases of lung cancer from 2009 to 2104, 612 (28.4%) were not treated. Risk of no treatment was higher in the following patients: patients in their 60s (odds ratio [OR], 1.18; 95% confidence interval [CI], 0.75 to 1.84), 70s (OR, 3.64; 95% CI, 2.41 to 5.50), and >80 years old (OR, 16.55; 95% CI, 10.53 to 25.03) than those in their 50s; patients with previous myocardial infarction (OR, 2.07; 95% CI, 1.01 to 4.25) or chronic kidney disease (OR, 2.88; 95% CI, 1.57 to 5.30); and patients diagnosed at a non-referral hospital (OR, 1.40; 95% CI, 1.01 to 1.92) or primary care provider (OR, 1.81; 95% CI, 1.43 to 2.29) compared with referral hospital. Low-income patients receiving Medicaid were 1.75 times (95% CI, 1.14 to 2.68) more likely to forgo treatment than high-income patients (upper 20%). Risk was not associated with sex or the year in which the lung cancer was diagnosed.
Conclusion
Age predominantly determines whether patients with lung cancer undergo anti-cancer treatment.

Citations

Citations to this article as recorded by

Age differences in the treatment of lung cancer–a cohort study among 42,000 patients from Germany
Nikolaj Rischke, Josephine Kanbach, Ulrike Haug
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Giant Ovarian Cyst Presenting as an Intra-Abdominal Mass
Dhruv Narayan, Archit Jain, Amit Shrivastava, Gunjan Jindal, Komal Yadav
Journal of Evolution of Medical and Dental Sciences.2022; 11(3): 428. CrossRef
Development and Validation of a Prognostic Nomogram in Lung Cancer With Obstructive Sleep Apnea Syndrome
Wei Liu, Ling Zhou, Dong Zhao, Xiaofeng Wu, Fang Yue, Haizhen Yang, Meng Jin, Mengqing Xiong, Ke Hu
Frontiers in Medicine.2022;[Epub] CrossRef
Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer
Seung Hun Jang, Dong Yoon Lee, Jihyeon Jeong, Won-Il Choi
The Korean Journal of Internal Medicine.2022; 37(4): 811. CrossRef
Effects of Nurse Navigators During the Transition from Cancer Screening to the First Treatment Phase: A Systematic Review and Meta-analysis
Jiwon Oh, Sukhee Ahn
Asian Nursing Research.2021; 15(5): 291. CrossRef
Small cell lung cancer starting with diabetes mellitus: Two case reports and literature review
Tong Zhou, Yao Wang, Xue Zhao, Yang Liu, Ying-Xuan Wang, Xiao-Kun Gang, Gui-Xia Wang
World Journal of Clinical Cases.2019; 7(10): 1213. CrossRef
Trends in life expectancy among medical aid beneficiaries and National Health Insurance beneficiaries in Korea between 2004 and 2017
Jinwook Bahk, Hee-Yeon Kang, Young-Ho Khang
BMC Public Health.2019;[Epub] CrossRef

7,672 View
145 Download
5 Web of Science
7 Crossref

Assessment of Chemotherapy Response Using FDG-PET in Pediatric Bone Tumors: A Single Institution Experience: Dong Hwan Kim, Seung Yeon Kim, Hyeon Jeong Lee, Bong Sup Song, Dong Ho Kim, Joong Bum Cho, Jung Sub Lim, Jun Ah Lee; Cancer Res Treat. 2011;43(3):170-175. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.170

Abstract PDF PubReader ePub

PURPOSE
Response to neo-adjuvant chemotherapy is an important prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). [F-18]-fluorodeoxy-D-glucose (FDG)-positron emission tomography (PET) is a non-invasive imaging modality that predicts histologic response to chemotherapy of various malignancies; however, limited data exist about the usefulness of FDG-PET in predicting the histologic response of pediatric bone tumors to chemotherapy. We analyzed the FDG-PET imaging characteristics of pediatric bone tumors and determined the association with response to chemotherapy.
MATERIALS AND METHODS
Pediatric patients with OS (n=19) or ESFT (n=17) were evaluated for FDG-PET standard uptake values before (SUV1) and after (SUV2) chemotherapy. The relationship to the chemotherapy response was assessed by histopathology in surgically-excised tumors. A complete data set (SUV1, SUV2, and histologic response) was available in 23 patients.
RESULTS
While the mean SUV1s were not different between patients with OSs and ESFTs (9.44 vs. 6.07, p=0.24), the SUV2s were greater in the patients with OSs than ESFTs (4.55 vs. 1.66, p=0.01). The ratios of SUV2-to-SUV1 (SUV2 : SUV1) were 0.65 and 0.35 for OS and ESFT, respectively (p=0.08). All of the patients with ESFTs and 47% of the patients with OS had a favorable histologic response to chemotherapy. The SUV2 : 1 [(SUV1-SUV2)/SUV1]> or =0.5 and SUV2< or =2.5 were related to favorable histologic responses to chemotherapy; the sensitivity and specificity of SUV2 : 1 at 0.5 and SUV2 at 2.5 were 93% and 88%, and 88% and 78%, respectively.
CONCLUSION
FDG-PET can be used as a non-invasive surrogate to predict response to chemotherapy in children with bone tumors.

Citations

Citations to this article as recorded by

18F-FDG PET/CT in the Management of Osteosarcoma
Chiwoo Oh, Michael W. Bishop, Steve Y. Cho, Hyung-Jun Im, Barry L. Shulkin
Journal of Nuclear Medicine.2023; 64(6): 842. CrossRef
[18F]FDG PET/CT quantitative parameters for the prediction of histological response to induction chemotherapy and clinical outcome in patients with localised bone and soft-tissue Ewing sarcoma
Alessio Annovazzi, Virginia Ferraresi, Vincenzo Anelli, Renato Covello, Sabrina Vari, Carmine Zoccali, Roberto Biagini, Rosa Sciuto
European Radiology.2021; 31(9): 7012. CrossRef
Different 18F‐FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors
Gihan El‐Hennawy, Hosna Moustafa, Walid Omar, Naglaa Elkinaai, Ahmad Kamel, Iman Zaki, Nesma Farid, Esraa El‐Kholy
Pediatric Blood & Cancer.2020;[Epub] CrossRef
Sarcomes osseux
J.L. Albérini, P.Y. Salaün
Médecine Nucléaire.2019; 43(1): 138. CrossRef
Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma
Antonio Ruggiero, Valerio Lanni, Alberto Librizzi, Palma Maurizi, Giorgio Attinà, Stefano Mastrangelo, Alessandro Giordano, Riccardo Riccardi
Journal of Pediatric Hematology/Oncology.2018; 40(4): 277. CrossRef
The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence
Andrea Angelini, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giulia Polverari, Giulia Trovarelli, Emanuela Palmerini, Stefano Ferrari, Stefano Fanti, Pietro Ruggieri
European Journal of Nuclear Medicine and Molecular Imaging.2017; 44(10): 1712. CrossRef
PET/CT of Osteosarcoma and Ewing Sarcoma
Colleen M. Costelloe, Hubert H. Chuang, Najat C. Daw
Seminars in Roentgenology.2017; 52(4): 255. CrossRef
Qualitative and Semi-Quantitative 18-F FDG PET/CT for Osteosarcoma: A Review
Lorenzo Nardo, Michelle Zhang, Luca Facchetti, Benjamin L. Franc
Current Radiology Reports.2017;[Epub] CrossRef
Tumour hypoxia: lessons learnt from preclinical imaging
Isabella Raccagni, Silvia Valtorta, Rosa Maria Moresco, Sara Belloli
Clinical and Translational Imaging.2017; 5(5): 407. CrossRef
Assessment of response to treatment in paediatric bone sarcomas by means of PET imaging
Natale Quartuccio, Byung Hyun Byun, Pierpaolo Alongi, Federico Caobelli, Chang-Bae Kong, Sang Moo Lim, Angelina Cistaro
Clinical and Translational Imaging.2016; 4(1): 41. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N. Machak, A. K. Morozov, A. I. Snetkov, I. N. Karpov, N. V. Kochergina, A. B. Bludov, A. D. Ryzhkov
Vestnik travmatologii i ortopedii imeni N.N. Priorova.2016; (3): 53. CrossRef
Modern Methods of Visualization in Diagnosis, Staging and Elaboration of Treatment Tactics for Primary Malignant Bone Tumors. Part I
G. N Machak, A. K Morozov, A. I Snetkov, I. N Karpov, N. V Kochergina, A. B Bludov, A. D Ryzhkov
N.N. Priorov Journal of Traumatology and Orthopedics.2016; 23(3): 53. CrossRef
Radiotherapy and gemcitabine–docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma
Jun Ah Lee, Eun Kyung Paik, Juhee Seo, Dong Ho Kim, Jung Sub Lim, Ji Young Yoo, Mi-Sook Kim
Japanese Journal of Clinical Oncology.2015; : hyv171. CrossRef
Tumor‐to‐background Ratio to Predict Response to Chemotherapy of Osteosarcoma Better than Standard Uptake Values
Jin‐peng He, Yun Hao, Mi Li, Jiang Wang, Feng‐jin Guo
Orthopaedic Surgery.2014; 6(2): 145. CrossRef
Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives
Emmy D.G. Fleuren, Yvonne M.H. Versleijen-Jonkers, Otto C. Boerman, Winette T.A. van der Graaf
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1845(2): 266. CrossRef
FDG PET/CT of Primary Bone Tumors
Colleen M. Costelloe, Hubert H. Chuang, John E. Madewell
American Journal of Roentgenology.2014; 202(6): W521. CrossRef
Atypical growth on MRI in a case of Ewing’s sarcoma despite lower SUV on PET
Zachary Sanford, Stanford Israelsen, Rajesh Sehgal, Felix H. Cheung
Skeletal Radiology.2014; 43(6): 819. CrossRef
Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models
Carmen Campanile, Matthias J.E. Arlt, Stefanie D. Krämer, Michael Honer, Ana Gvozdenovic, Patrick Brennecke, Cindy R. Fischer, Adam A. Sabile, Adrienne Müller, Simon M. Ametamey, Walter Born, Roger Schibli, Bruno Fuchs
Journal of Nuclear Medicine.2013; 54(8): 1362. CrossRef
Promise and pitfalls of quantitative imaging in oncology clinical trials
Brenda F. Kurland, Elizabeth R. Gerstner, James M. Mountz, Lawrence H. Schwartz, Christopher W. Ryan, Michael M. Graham, John M. Buatti, Fiona M. Fennessy, Edward A. Eikman, Virendra Kumar, Kenneth M. Forster, Richard L. Wahl, Frank S. Lieberman
Magnetic Resonance Imaging.2012; 30(9): 1301. CrossRef
18F NaF PET/CT in the Assessment of Malignant Bone Disease
Camila Mosci, Andrei Iagaru
PET Clinics.2012; 7(3): 263. CrossRef
The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma
Carmelo Caldarella, Marco Salsano, Maria Antonietta Isgrò, Giorgio Treglia
International Journal of Molecular Imaging.2012; 2012: 1. CrossRef

12,391 View
71 Download
21 Crossref

Case Report

Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management: Kang Min Lee, Hee Woo Lee, Seung Yeon Kim, Hyeon Jeong Lee, Dong Hwan Kim, Joongbum Cho, Dong Ho Kim, Jung Sub Lim, Jin Kyung Lee, Jun Ah Lee; Cancer Res Treat. 2011;43(1):67-70. Published online March 31, 2011; DOI: https://doi.org/10.4143/crt.2011.43.1.67

Abstract PDF PubReader ePub

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Citations

Citations to this article as recorded by

The Role of Single Nucleotide Polymorphisms in Transporter Proteins and the Folate Metabolism Pathway in Delayed Methotrexate Excretion: A Case Report and Literature Review
Jun Wang, Yue-Tao Zhao, Meng-Jiao Sun, Feng Chen, Hong-Li Guo
Pharmacogenomics and Personalized Medicine.2022; Volume 15: 919. CrossRef
Toxicité rénale des anticancéreux
Blandine Aloy, Nicolas Janus, Corine Isnard-Bagnis, Gilbert Deray, Vincent Launay-Vacher
Néphrologie & Thérapeutique.2021; 17(7): 553. CrossRef
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
Wei Zhang, Qing Zhang, Ting-Ting Zheng, Jian-Cun Zhen, Xiao-Hui Niu
Chinese Medical Journal.2016; 129(21): 2530. CrossRef

8,783 View
53 Download
3 Crossref

Original Article

Comparison of 30 mg and 40 mg of Mitomycin C Intravesical Instillation in Korean Superficial Bladder Cancer Patients: Prospective, Randomized Study: Chang Wook Jeong, Hwang Gyun Jeon, Cheol Kwak, Hyeon Jeong, Sang Eun Lee; Cancer Res Treat. 2005;37(1):44-47. Published online February 28, 2005; DOI: https://doi.org/10.4143/crt.2005.37.1.44

Abstract PDF PubReader ePub

Purpose

A prospective study was performed to compare the efficacy and safety of intravesical mitomycin C (MMC) instillation for the prophylaxis of bladder cancer at different concentrations (30 mg or 40 mg).

Materials and Methods

Ninety-seven patients that received complete transurethral resection for superficial bladder cancer were divided into two-randomized groups. One group (n=53) received 30 mg and the other group (n=44) received 40 mg dose of MMC weekly for 8 weeks, which was followed monthly for 10 months as maintenance therapy. The recurrence rates and side effects in both groups were recorded. The mean follow-up period was 32.4 months in the 30 mg group, and 32.0 months in the 40 mg group.

Results

The overall one and two year recurrence rates were 19% and 24% in the 30 mg group, and 12% and 22% in the 40 mg group, which was not significantly different (p>0.05). Most of the side effects were mild and transient. Moreover, the rates of the individual side effects were not statistically different in the two groups.

Conclusion

Our comparison of 30 mg and 40 mg intravesical MMC instillation showed no difference in either response or side effects. Thus, we tentatively conclude that we can use 30 mg instead of 40 mg as an intravesical MMC instillation dose.

Citations

Citations to this article as recorded by

Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment
Marom Yosef, Svetlana Bunimovich-Mendrazitsky
Frontiers in Oncology.2024;[Epub] CrossRef
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis
Pietro Scilipoti, Aleksander Ślusarczyk, Mario de Angelis, Francesco Soria, Benjamin Pradere, Wojciech Krajewski, David D’Andrea, Andrea Mari, Francesco Del Giudice, Renate Pichler, José Daniel Subiela, Luca Afferi, Simone Albisinni, Laura Mertens, Ekater
European Urology Oncology.2024;[Epub] CrossRef
Gestion pratique de l’ECBU au cours des instillations endovésicales de Bacille de Calmette et Guérin (BCG) et de Mitomycine C (MMC)
F. Saint
Progrès en Urologie - FMC.2021; 31(4): F121. CrossRef
Loco-regional deep hyperthermia combined with intravesical Mitomycin instillation reduces the recurrence of non-muscle invasive papillary bladder cancer
Yu-Ching Wen, Liang-Ming Lee, Yung-Wei Lin, Syuan-Hao Syu, Ke-Hsun Lin, Yen-Chun Fan, Hsin-Lun Lee, Benjamin Chung Howe Lai, Hung-Jen Shih
International Journal of Hyperthermia.2021; 38(1): 1627. CrossRef
Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder
Sunita Saxena, Usha Agrawal, Abhilasha Agarwal, Nandagudi Srinivasa Murthy, Nayan Kumar Mohanty
BJU International.2006; 98(5): 1012. CrossRef

7,868 View
58 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search